Enter Your Details Below

Get Investor Fraud News Updates


October 14, 2024

Edwards Lawsuit Submission Form
According to the complaint, defendants provided investors with material information concerning Edwards’ expected revenue for the fiscal year 2024, particularly as it related to the growth of the Company’s core product, Transcatheter Aortic Valve Replacement (“TAVR”). Defendants’ statements...
Learn More
According to the complaint, defendants provided investors with material information concerning Edwards’ expected revenue for the fiscal year 2024, particularly as it related to the growth of the Company’s core product, Transcatheter Aortic Valve Replacement (“TAVR”). Defendants’ statements included, among other things, strong commitment to the TAVR platform, confidence in the Company’s ability to capitalize on a subset of untreated patients through scaling of its various patient activation activities, and continued claims of significant demand in allegedly lower-penetrated markets. On July 24, 2024, Edwards unveiled below-expectation financial results for the second quarter of fiscal 2024 and, in particular, slashed its revenue guidance for the TAVR platform for the full fiscal year 2024. The Company attributed the TAVR setback on the “continued growth and expansion of structural heart therapies … [which] put pressure on hospital workflows.” Investors understood this to mean that developments in new procedures, including defendant’s own Transcatheter Mitral and Tricuspid Therapies (“TMTT”), put significant strain on hospital structural heart teams such that they were underutilizing TAVR, despite the Company’s continued claim of a significantly undertreated patient population. Moreover, the Company announced three acquisitions during the second quarter designed to embolden their treatments alternative to TAVR, suggesting further that the company was aware of the potential for the TAVR platform’s decelerated growth. Investors and analysts reacted immediately to Edwards’ revelations. The price of Edwards’ common stock declined dramatically. From a closing market price of $86.95 per share on July 24, 2024, Edwards’ stock price fell to $59.70 per share on July 25, 2024, a decline of about 31.34% in the span of just a single day.

Active Cases

Ticker Symbol Company Name Join Deadline Join
CXM Sprinklr, Inc. October 15, 2024 Join
STLA Stellantis N.V. October 15, 2024 Join
SYM Symbotic Inc. October 15, 2024 Join
EXTR Extreme Networks, Inc. October 15, 2024 Join
PDD PDD Holdings Inc. f/k/a Pinduoduo Inc. October 15, 2024 Join
ARDX Ardelyx, Inc. October 15, 2024 Join
OFIX Orthofix Medical Inc. October 21, 2024 Join
DXCM DexCom, Inc. October 21, 2024 Join
SPIR Spire Global, Inc. October 21, 2024 Join
STM STMicroelectronics N.V. October 22, 2024 Join
DAVA Endava plc October 25, 2024 Join
MEI Methode Electronics, Inc. October 25, 2024 Join
SAGE Sage Therapeutics, Inc. October 28, 2024 Join
VERV Verve Therapeutics, Inc. October 28, 2024 Join
SBUX Starbucks Corporation October 28, 2024 Join
OM Outset Medical, Inc. October 28, 2024 Join
SMCI Super Micro Computer, Inc. October 29, 2024 Join
ZI ZoomInfo Technologies Inc. November 04, 2024 Join
WBTN WEBTOON Entertainment Inc. November 04, 2024 Join
GTLB GitLab Inc. November 04, 2024 Join
GTLB GitLab Inc. November 04, 2024 Join
AGEN Agenus Inc. November 05, 2024 Join
NFE New Fortress Energy Inc. November 18, 2024 Join
MGX Metagenomi, Inc. November 25, 2024 Join
BMBL Bumble Inc. November 25, 2024 Join
UPS United Parcel Service, Inc. December 09, 2024 Join
EW Edwards Lifesciences Corporation December 13, 2024 Join